Journal editorial - The emerging story of Myval transcatheter heart valve: lessons from the LANDMARK trial
ESC Cardio Talk
00:00
Paravalvular leak and device type
Marie-Annick compares PVL rates: low for Myval and Sapien (<3%), slightly higher for Evolut (~6%).
Play episode from 04:05
Transcript
